An emerging leader in the immunotherapy space, we are advancing a pre-clinical pipeline of therapeutic candidates intended to elicit broad and durable anti-tumor and anti-viral responses and cure disease.

Stock Quote

Current value on NASDAQ*

*Stock Price may not reflect real time results

SEC Filings

U.S. Securities and Exchange Commission filings
View SEC Filings

Investor Contact

Will  O’Conner
Stern Investor Relations

Indaptus Management

View Management Team

Indaptus Board of Directors

View Board of Directors


November 15, 2021

Investor Presentation